Floatz logo

Catequentinib

Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Small moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Zimberelimab
University of Texas Southwestern Medical Center
Phase 2CCC
Domvanalimab
University of Texas Southwestern Medical Center
Phase 2CCC
Azacitidine
Forma Therapeutics, Inc.
Phase 1/2CCC
Nivolumab
Forma Therapeutics, Inc.
Phase 1/2CCC
CIS-DIAMMINEDICHLOROPLATINUM II
Forma Therapeutics, Inc.
Phase 1/2CCC

View all 9 →

Same molecule, other indications

Catequentinib is also rated in:

AnlotinibDormant
BB
Indicative ·
71 / 100
View asset →
refractory malignant neoplasmDormant
BB
Indicative ·
70 / 100
View asset →
kidney cancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →